12/2
08:00 am
cmmb
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
Medium
Report
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
11/25
01:49 pm
cmmb
Chemomab Therapeutics (NASDAQ:CMMB) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Chemomab Therapeutics (NASDAQ:CMMB) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/24
08:00 am
cmmb
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
Medium
Report
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
11/20
08:00 am
cmmb
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
High
Report
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
11/20
06:02 am
cmmb
Chemomab Therapeutics (NASDAQ:CMMB) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
High
Report
Chemomab Therapeutics (NASDAQ:CMMB) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
11/7
01:12 am
cmmb
Chemomab Therapeutics (NASDAQ:CMMB) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Chemomab Therapeutics (NASDAQ:CMMB) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/6
08:38 am
cmmb
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis [Yahoo! Finance]
Low
Report
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis [Yahoo! Finance]
11/6
08:00 am
cmmb
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
Medium
Report
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
11/4
05:31 pm
cmmb
Cholestatic Pruritus Market is Predicted to Exhibit Remarkable Growth at a CAGR of 23.4% in the US During the Forecast Period (2025-2034) | DelveInsight
Low
Report
Cholestatic Pruritus Market is Predicted to Exhibit Remarkable Growth at a CAGR of 23.4% in the US During the Forecast Period (2025-2034) | DelveInsight
11/4
05:31 pm
cmmb
Cholestatic Pruritus Market is Predicted to Exhibit Remarkable Growth at a CAGR of 23.4% in the US During the Forecast Period (2025-2034) | DelveInsight
Low
Report
Cholestatic Pruritus Market is Predicted to Exhibit Remarkable Growth at a CAGR of 23.4% in the US During the Forecast Period (2025-2034) | DelveInsight
10/22
06:56 am
cmmb
Chemomab Therapeutics (NASDAQ:CMMB) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Medium
Report
Chemomab Therapeutics (NASDAQ:CMMB) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.